Hytrin



  • Hytrin® 1mg tablet
  • Hytrin® 2mg tablet
  • Hytrin® 5mg tablet

Hytrin® (terazosin hydrochloride) is an alpha-blocker that is indicated for treatment of sympomatic benign prostatic hyperplasia (BPH). A significant improvement is noted in as early as 2 weeks, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH with evidence of sustained efficacy for up to 52 weeks of treatment.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.